Extended release of a novel antidepressant, venlafaxine, based on anionic polyamidoamine dendrimers and poly(ethylene glycol)-containing semi-interpenetrating networks

Journal of Biomedical Materials Research - Part A

Volumn 72, Issue 1, 2005, Pages 107-114

  Yang, Hu ^a   Lopina, Stephanie T ^a  

^a The University of Akron   (United States)

Author keywords

Extended release; Polyacrylamide hydrogel; Polyamidoamine (PAMAM) dendrimer; Polyethylene glycol; Semi interpenetrating network (IPN); Starburst ; Venlafaxine

Indexed keywords

CHEMICAL BONDS; CROSSLINKING; DENDRIMERS; ESTERS; FOURIER TRANSFORM INFRARED SPECTROSCOPY; HYDROGELS; HYDROLYSIS; INTERPENETRATING POLYMER NETWORKS; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POLYAMIDES; POLYETHYLENE GLYCOLS; SOLUBILITY;

ANTIDEPRESSANT; DRUG ADMINISTRATION; POLYAMIDOAMINE; VENLAFAXINE;

DRUG PRODUCTS;

ACRYLAMIDE; AMIDE; AMINE; ANION; ANTIDEPRESSANT AGENT; DENDRIMER; ESTER; MACROGOL; POLYAMIDOAMINE; UNCLASSIFIED DRUG; VENLAFAXINE;

ARTICLE; CONCENTRATION (PARAMETERS); CONJUGATE; COVALENT BOND; CROSS LINKING; HYDROGEL; INFRARED SPECTROSCOPY; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE; SUSTAINED DRUG RELEASE;

ACRYLAMIDE; ANIONS; ANTIDEPRESSIVE AGENTS; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; HYDROGELS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR WEIGHT; PERMEABILITY; POLYAMINES; POLYETHYLENE GLYCOLS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 10344222643     PISSN: 00219304     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbm.a.30220     Document Type: Article

References (47)

1. Haskins JT, Moyer JA, Muth EA, Sigg EB. DMI, Wy-45,030, Wy-45,881 and ciramadol inhibit locus coeruleus neuronal activity. Eur J Pharmacol 1985;115(2-3):139-146.
2. Ellingrod VL, Perry PJ. Venlafaxine: a heterocyclic antidepressant. Am J Hosp Pharm 1994;51(24):3033-3046.
3. Olver JS, Burrows GD, Norman TR. Third-generation antidepressants: do they offer advantages over the SSRIs? CNS Drugs 2001;15(12):941-954.
4. Burnett FE, Dinan TG. The clinical efficacy of venlafaxine in the treatment of depression. Rev Contemp Pharmacother 1998;9(5):303-320.
5. Klamerus KJ, Maloney K, Rudolph RL, Sisenwine SF, Jusko WJ, Chiang ST. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol 1992;32(8):716-724.
6. Burnett FE, Dinan TG. Venlafaxine: pharmacology and therapeutic potential in the treatment of depression. Hum Psychopharmacol 1998;13(3):153-162.
7. Mendels J, Johnston R, Mattes J, Riesenberg R. Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacol Bull 1993;29(2):169-174.
8. Clerc GE, Ruimy P, Verdeau-Palles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychopharmacol 1994;9(3): 139-143.
9. Cunningham LA. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group. Ann Clin Psychiatry 1997;9(3):157-164.
10. Feighner JP, Entsuah AR, McPherson MK. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients. J Affect Disord 1998;47(1-3):55-62.
11. Entsuah R, Chitra R. A benefit-risk analysis of once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Psychopharmacol Bull 1997;33(4):671-676.
12. Makhija SN, Vavia PR. Once daily sustained release tablets of venlafaxine, a novel antidepressant. Eur J Pharm Biopharm 2002;54(1):9-15.
13. Tomalia DA, Baker H, Dewald J, Hall M, Kallos G, Martin S, Roeck J, Ryder J, Smith P. A new class of polymers: Starburstdendritic macromolecules. Polym J (Tokyo) 1985;17(1):117-132.
14. Tomalia DA, Baker H, Dewald J, Hall M, Kallos G, Martin S, Roeck J, Ryder J, Smith P. Dendritic macromolecules: synthesis of Starburst dendrimers. Macromolecules 1986;19(9):2466-2468.
15. Newkome GR, Yao Z, Baker GR, Gupta VK. Micelles. Part 1. Cascade molecules: a new approach to micelles. A [27]-arborol. J Org Chem 1985;50(11):2003-2004.
16. Bosman AW, Janssen HM, Meijer EW. About dendrimers: structure, physical properties, and applications. Chem Rev 1999;99(7):1665-1688.
17. Hawker CJ, Wooley KL, Frechet JMJ. Unimolecular micelles and globular amphiphiles: dendritic macromolecules as novel recyclable solubilization agents. J Chem Soc Perkin Trans 1 1993(12):1287-1297.
18. Liu M, Frechet JMJ. Preparation, MALDI-TOF analysis, and micelle-like behavior of alkyl-modified poly(propylene imine) dendrimers. Polym Bull (Berlin) 1999;43(4-5):379-386.
19. Liu M, Kono K, Frechet JMJ. Water-soluble dendritic unimolecular micelles: their potential as drug delivery agents. J Controlled Release 2000;65(1-2):121-131.
20. Yang H, Morris JJ, Lopina ST. Polyethylene glycol-polyamidoamine dendritic micelle as solubility enhancer and the effect of the length of polyethylene glycol arms on the solubility of pyrene in water. J Colloid Interface Sci 2004;273(1):148-154.
21. Liu M, Frechet JMJ. Designing dendrimers for drug delivery. Pharm Sci Technol Today 1999;2(10):393-401.
22. Esfand R, Tomalia DA. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov Today 2001;6(8):427-436.
23. Poxon SW, Mitchell PM, Liang E, Hughes JA. Dendrimer delivery of oligonucleotide. Drug Delivery 1996;3(4):255-261.
24. Wiwattanapatapee R, Carreno-Gomez B, Malik N, Duncan R. PAMAM dendrimers as a potential oral drug delivery system: uptake by everted rat intestinal sacs in vitro. J Pharm Pharmacol 1998;50(Suppl):99.
25. Liu M, Kono K, Frechet JMJ. Water-soluble dendrimer-poly-(ethylene glycol) starlike conjugates as potential drug carriers. J Polym Sci Part A: Polym Chem 1999;37(17):3492-3503.
26. Twyman LJ, Beezer AE, Esfand R, Hardy MJ, Mitchell JC. The synthesis of water soluble dendrimers, and their application as possible drug delivery systems. Tetrahedron Lett 1999;40(9): 1743-1746.
27. Bielinska AU, Yen A, Wu HL, Zahos KM, Sun R, Weiner ND, Baker JR Jr, Roessler BJ. Application of membrane-based dendrimer/DNA complexes for solid phase transfection in vitro and in vivo. Biomaterials 2000;21(9):877-887.
28. Malik N, Wiwattanapatapee R, Klopsch R, Lorenz K, Frey H, Weener JW, Meijer EW, Paulus W, Duncan R. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 1251-labeled polyamidoamine dendrimers in vivo. J Controlled Release 2000;65(1-2):133-148.
29. Luo D, Haverstick K, Belcheva N, Han E, Saltzman WM. Polyethylene glycol-conjugated PAMAM dendrimer for bio-compatible, high-efficiency DNA delivery. Macromolecules 2002;35(9):3456-3462.
30. Yang H, Lopina ST. Penicillin V-conjugated PEG-PAMAM star polymers. J Biomater Sci Polym Ed 2003;14(10):1043-1056.
31. Singh P. Terminal groups in Starburst dendrimers: activation and reactions with proteins. Bioconjug Chem 1998;9(1):54-63.
32. Zalipsky S, Gilon C, Zilkha A. Attachment of drugs to polyethylene glycols. Eur Polym J 1983;19(12):1177-1183.
33. Nathan A, Zalipsky S, Ertel SI, Agathos SN, Yarmush ML, Kohn J. Copolymers of lysine and polyethylene glycol: a new family of functionalized drug carriers. Bioconjug Chem 1993;4(1):54-62.
34. Bajpai AK, Bhanu S. Controlled release of a digestive enzyme from a swellable semi-interpenetrating polymer network (IPN). J Macromol Sci Pure Appl Chem 2003;A40(3):265-292.
35. Baker JP, Hong LH, Blanch HW, Prausnitz JM. Effect of initial total monomer concentration on the swelling behavior of cationic acrylamide-based hydrogels. Macromolecules 1994;27(6): 1446-1454.
36. Veronese FM, Morpurgo M. Bioconjugation in pharmaceutical chemistry. Farmaco 1999;54(8):497-516.
37. Woller EK, Cloninger MJ. Mannose functionalization of a sixth generation dendrimer. Biomacromolecules 2001;2(3):1052-1054.
38. Park K, Shalaby WSE, Park H. Biodegradable hydrogels for drug delivery. Boca Raton, FL: CRC Press; 1993. 261 p.
39. Canal T, Peppas NA. Correlation between mesh size and equilibrium degree of swelling of polymeric networks. J Biomed Mater Res 1989;23(10):1183-1193.
40. Bohdanecky M, Petrus V, Sedlacek B. Estimation of the characteristic ratio of polyacrylamide in water and in a mixed theta-solvent. Makromol Chem 1983;184(10):2061-2073.
41. Flory PJ. Principles of polymer chemistry. New York: Cornell University Press; 1953.
42. Kayaman N, Hamurcu EEG, Uyanik N, Baysal BM. Interpenetrating hydrogel networks based on polyacrylamide and poly(itaconic acid). Synthesis and characterization. Macromol Chem Phys 1999;200(1):231-238.
43. De Gennes PG. Scaling concepts in polymer physics. Ithaca, NY: Cornell University Press; 1979. 324 p.
44. De Gennes PG. Dynamics of entangled polymer solutions. I. The Rouse model. Macromolecules 1976;9(4):587-593.
45. Bajpai AK, Bhanu S. In vitro release dynamics of insulin from a loaded hydrophilic polymeric network. J Mater Sci Mater Med 2004;15(1):43-54.
46. Roberts JC, Bhalgat MK, Zera RT. Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. J Biomed Mater Res 1996;30(1):53-65.
47. Muniz EC, Geuskens G. Polyacrylamide hydrogels and semi-interpenetrating networks (IPNs) with poly(N-isopropylacrylamide): mechanical properties by measure of compressive elastic modulus. J Mater Sci Mater Med 2001;12(10-12):879-881.